£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumou ...

LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the fo ...

行业 - 生物技术股票有着永久相关的故事线因为健康比财富更重要这一主题行业受益于解决人类健康问题的广泛推动常吸引大量投资资金[1] - 2023年全球生物技术领域估值达1.55万亿美元2024 - 2030年可能以13.96%的复合年增长率扩张达到3.88万亿美元[2] Esperion公司 - 位于密歇根州安阿伯市属于医疗保健行业的药品制造类别开发和商业化用于治疗低密度脂蛋白胆固醇升高患者的药物主要关注特定疾病患者[3] - 分析师一致给予适度买入评级平均目标价7.41美元意味着超156%的上涨潜力最高目标价16美元意味着较周三收盘价近454%的增长最不乐观目标价2.90美元与当前价格持平[3] - 2024财年覆盖专家预计每股亏损4美分较去年2.03美元的亏损有显著改善预计营收3.2439亿美元较上一年增长近179%[4] ADC Therapeutics公司 - 位于瑞士专注于开发其专有抗体药物偶联物或ADC技术其核心药物Zynlonta已获美国食品药品监督管理局加速批准用于治疗特定类型淋巴瘤[5] - 分析师一致给予强力买入评级该观点来自六位专家平均目标价10美元意味着超216%的上涨潜力最高目标价达每股13美元[5] - 分析师预计2024财年每股亏损1.89美元较2023年2.94美元的亏损有很大改善预计营收7782万美元较去年的6956万美元增长11.9%[6] Autolus Therapeutics公司 - 位于英国是一家临床阶段企业正在开发T细胞疗法以解决癌症问题还有一个业务部门专注于自身免疫性疾病自身免疫性疾病呈上升趋势公司拥有巨大的潜在市场[7] - 分析师一致给予强力买入评级该评估来自四位专家平均目标价9.75美元意味着近125%的上涨潜力最高目标价11美元意味着153%的上涨潜力[7] - 2024财年覆盖专家认为每股将亏损78美分较去年1.20美元的亏损有所改善预计销售额达1782万美元较去年170万美元增长949.5%[8]

LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website at ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. Abo ...

LAUSANNE, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 2:00 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website ir.adctherapeutics.com. A replay of the webcast will be available fo ...

LAUSANNE, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 2:00 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website ir.adctherapeutics.com. A replay of the webcast will be available fo ...

LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website ir.adctherapeutics.com. A replay of the webcast will be available for approximate ...

LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website ir.adctherapeutics.com. A replay of the webcast will be available for approximat ...

财务数据和关键指标变化 - 第一季度ZYNLONTA净销售额为1780万美元,较上年同期下降6%,主要是由于毛利率折扣增加和销量下降,部分被价格上涨所抵消 [7] - 第一季度总运营费用(非GAAP)同比下降16%,主要反映了公司专注于提高运营效率,以及研发支出和销售及营销费用的减少 [28] - 第一季度GAAP净亏损4660万美元,非GAAP调整后净亏损3110万美元,主要由于运营费用的降低 [29] 各条业务线数据和关键指标变化 - ZYNLONTA在学术中心和社区医疗机构的销售均有增长,尽管面临更加激烈的竞争环境 [7] 各个市场数据和关键指标变化 - 无相关内容 公司战略和发展方向及行业竞争 - 公司将主要资本投入到ZYNLONTA业务,以商业化现有三线治疗DLBCL适应症,并拓展至二线及更早期DLBCL和缓慢进展性淋巴瘤(如边缘带淋巴瘤)的更大潜在机会 [11][12][13] - 公司正在推进LOTIS-5和LOTIS-7研究,以拓展ZYNLONTA在二线及更早期DLBCL的适应症 [12][13] - 公司看好ZYNLONTA在边缘带淋巴瘤二线及更早期治疗的潜力,正在推进一项50例的II期临床试验 [14][16][17][21] - 公司正在推进固体瘤管线,ADCT-601是最先进的资产,同时还有一系列基于新型exatecan平台的ADC候选药物 [24][25] 管理层对经营环境和未来前景的评论 - 公司保持了资本配置的纪律,第一季度非GAAP运营费用同比下降16%,有助于控制现金消耗 [9] - 公司完成1.05亿美元的增发,预计可延长现金储备至2026年中期,为执行战略提供更大的财务灵活性 [10] - 公司对ZYNLONTA在DLBCL和边缘带淋巴瘤等适应症的拓展前景充满信心,同时也看好固体瘤管线的发展潜力 [11][18][24] 问答环节重要的提问和回答 问题1 **Yun Zhong 提问** 公司是否计划推进边缘带淋巴瘤和滤泡性淋巴瘤的临床研究,哪一个适应症有可能首先进入公司自主的注册研究 [37][38][39][40] **Ameet Mallik 回答** 公司正在扩大边缘带淋巴瘤和滤泡性淋巴瘤的临床试验规模,计划同步推进监管和指南策略 边缘带淋巴瘤的临床试验基础更加充实,可能会更快进入公司自主的注册研究 [38][39][40] 问题2 **Michael Schmidt 提问** 边缘带淋巴瘤试验中患者的反应持续时间如何,与其他治疗方案相比如何 [43][44][45][46] 有一例患者因毒性反应而停药,具体情况如何 [46] **Ameet Mallik 和 Mohamed Zaki 回答** 目前已有1例患者反应持续20个月,大部分患者反应持续时间超过10个月,这优于既往报道的15-18个月 公司了解到1例患者在4个疗程后因毒性反应停药,但该患者仍保持完全缓解,毒性反应在停药后完全消失 [44][45][46] 问题3 **Unidentified Analyst 提问** CD20双特异性抗体的竞争对ZYNLONTA在三线DLBCL市场的影响是否已经完全体现 [56][57][58][59][60] Roche最近宣布其二线DLBCL试验达到主要终点,是否会对LOTIS-5的ZYNLONTA联合方案构成威胁 [56][57][58][59][60] **Ameet Mallik 和 Kristen Harrington-Smith 回答** CD20双特异性抗体在学术中心三线DLBCL市场获得一定份额,但公司在学术中心和社区医疗机构的ZYNLONTA销售仍保持增长 Roche二线DLBCL试验结果尚未公开,需要进一步了解其疗效和安全性数据,但公司相信ZYNLONTA联合方案在疗效和安全性方面具有优势 [58][59][60]